Abstract:Key PointsThrough crosstalk with the intestinal microbiota, the innate immune system regulates intestinal homeostasis by conditioning the immune response both at mucosal sites and systemically, and by providing instructive signals that drive intestinal epithelial cell turnover and mucosal regeneration. The innate immune system is also a crucial modifier of bacterial handling through autophagy and a determinant of intestinal epithelial cell survival and apoptosis.Although excessive Toll-like receptor (TLR) activation in the gut is pathogenic, sensing of the commensal flora by these receptors, particularly TLR2 and TLR4, is required for intestinal homeostasis and control of tissue repair. In addition, apical TLR9 stimulation triggers mucosal tolerance through induction of type I interferons that have been proposed to protect from colonic inflammation.Nucleotide-binding oligomerization domain (NOD) receptors have a paramount role in intestinal homeostasis, and genetic mutations and single-nucleotide polymorphisms (SNPs) in their genes are associated with Crohn's disease. It is generally accepted that alterations in NOD2 function affect susceptibility to IBD because of the key role of this receptor in linking innate signals to the induction of adaptive immune tolerance to the intestinal microbiota. NOD2 modulates TLR signalling, regulates the production of defensins and IL-10, and polarizes the adaptive immune response towards a TH2-type response. More recently, NOD2 was shown to trigger autophagy in response to bacterial sensing through an interaction with the autophagy protein ATG16L1 (autophagy-related 16-like 1).Genetic studies of Crohn's disease, including genome-wide association studies, uncovered two autophagy loci — ATG16L1 and IRGM — that are linked to Crohn's disease susceptibility. Deficiency in ATG16L1 function not only affects the ability of NOD2 to trigger autophagy, but also affects Paneth cells and renders macrophages hyperresponsive to TLR agonists, which leads to excessive inflammasome activation. This suggests that aberrant bacterial handling could act as a trigger for inflammation in Crohn's disease.A SNP in the human NOD-, LRR- and pyrin domain-containing 3(NLRP3) region that downregulates NLRP3 expression is associated with Crohn's disease susceptibility. Consistently, the NLRP3 inflammasome–caspase 1–IL-18–IL-18R–MYD88 axis of inflammation is required for tissue repair following injury and is protective from colitis and colitis-associated colorectal cancer in mouse models.Negative regulators of innate immunity pathways, including SIGIRR (single immunoglobulin IL-1-related receptor), SOCS1 (suppressor of cytokine signalling 1) and caspase 12, are important effectors of intestinal immune tolerance. Deletion of their respective genes leads to amplification of the intestinal inflammatory response and promotion of colorectal cancer.

Critical role for the NLRP3 inflammasome in colitis and colitis associated colorectal cancer (47.9)

NLRP3 inflammasome in colitis and colitis-associated colorectal cancer

The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer

NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis

IL-18 Production Downstream of the Nlrp3 Inflammasome Confers Protection against Colorectal Tumor Formation

Does NLRP3 Inflammasome and Aryl Hydrocarbon Receptor Play an Interlinked Role in Bowel Inflammation and Colitis-Associated Colorectal Cancer?

NLRP3 Inflammasome and Inflammatory Bowel Disease

NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease

Colorectal Cancer and NLRP-Current Knowledge

The Pathogenic Role of NLRP3 Inflammasome Activation in Inflammatory Bowel Diseases of Both Mice and Humans.

Innate immune mechanisms of colitis and colitis-associated colorectal cancer

The role of NLRP3 inflammasome in colorectal cancer: potential therapeutic target

CCN3 aggravates intestinal inflammation in inflammatory colitis through regulating NLRP3 inflammasome in macrophages

NLRC4, inflammation and colorectal cancer (Review)

The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity

Investigating the Role of the NLRP3 Inflammasome Pathway in Acute Intestinal Inflammation: Use of THP-1 Knockout Cell Lines in an Advanced Triple Culture Model

A Critical Role of NLRP3 Inflammasome in Boosting Antigen-Specific Immunity

Epithelial Nlrp10 inflammasome mediates protection against intestinal autoinflammation

Inhibition of NLRP3 Attenuates Sodium Dextran Sulfate-Induced Inflammatory Bowel Disease Through Gut Microbiota Regulation.

The NLRP3 inflammasome: contributions to inflammation-related diseases